Merkel cell carcinoma: Two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 205-210

  Yao, Min ^a,b   Smith, Russell B ^a   Hoffman, Henry T ^a   Funk, Gerry F ^a   Graham, Michael M ^a   Buatti, John M ^a  

^a UNIVERSITY OF IOWA HEALTH CARE   (United States)

^b W189Z General Hospital   (United States)

Author keywords

Carcinoma staging; Case report; FDG PET; Human; Merkel cell carcinoma; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOGRANIN; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN AE3; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CHEMOSURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; MINIMAL RESIDUAL DISEASE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CARCINOMA, MERKEL CELL; CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS;

EID: 17044437335     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000144850.68142.68     Document Type: Article

References (23)

1. Toker C. Trabecular carcinoma of the skin. A question of title. Am J Dermatopathol. 1982;4:497-500.
2. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991;126:1514-1519.
3. Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8:204-208.
4. Hitchcock CL, Bland KI, Laney RG III, et al. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg. 1988;207:201-207.
5. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. 1992;102:244-249.
6. Goepfert H, Remmler D, Silva E, et al. Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolaryngol. 1984;110:707-712.
7. Gollub MJ, Gruen DR, Dershaw DD. Merkel cell carcinoma: CT findings in 12 patients. AJR Am J Roentgenol. 1996;167:617-620.
8. Eftekhari F, Wallace S, Silva EG, et al. Merkel cell carcinoma of the skin: imaging and clinical features in 93 cases. Br J Radiol. 1996;69: 226-233.
9. Nguyen BD, McCullough AE. Imaging of Merkel cell carcinoma. Radiographics. 2002;22:367-376.
10. Stokkel MP, Draisma A, Pauwels EK. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol. 2001;127:278-285.
11. Tucker R, Coel M, Ko J, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol. 2001;19:2504-2508.
12. Pauwels EK, Sturm EJ, Bombardieri E, et al. Positron-emission tomography with [18F]fluorodeoxyglucose. Part 1. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 2000;126:549-559.
13. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol. 2000;126:560-574.
14. Lampreave JL, Benard F, Alavi A, et al. PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma. J Nucl Med. 1998;39:2087-2090.
15. Wong CO, Pham AN, Dworkin HJ. F-18 FDG accumulation in an octreotide negative Merkel cell tumor. Clin Positron Imaging. 2000;3: 71-73.
16. Nguyen BD. Positron emission tomographic imaging of Merkel cell carcinoma. Clin Nucl Med. 2002;27:922-923.
17. Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol. 2002;20:588-598.
18. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
19. Carnaille B, Nocaudie M, Pattou F, et al. Scintiscans and carcinoid tumors. Surgery. 1994;116:1118-1121; discussion 1121-1112.
20. Kwekkeboom DJ, Hoff AM, Lamberts SW, et al. Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol. 1992;128: 818-821.
21. Straka JA, Straka MB. A review of Merkel cell carcinoma with emphasis on lymph node disease in the absence of a primary site. Am J Otolaryngol. 1997;18:55-65.
22. Voog E, Biron P, Martin JP, et al. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85: 2589-2595.
23. Schwarte DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173-1178.